Feb. 15, 2019
- Locke FL, et al. Clinical and biologic covariates of outcomes in zuma-1: A pivotal trial of axicabtagene ciloleucel (AXI-CEL; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphoma (NHL). Presentation. 2017 annual meeting of European Hematology Association, June 24, 2017, Madrid, Spain. https://learningcenter.ehaweb.org/eha/2017/22nd/181753/yi.lin.clinical.and.biologic.covariates.of.outcomes.in.zuma-1.a.pivotal.trial.html?f=m3. Accessed Oct. 27, 2017.
- Neelapu SS, et al. Chimeric antigen receptor T-cell therapy: Assessment and management of toxicities. Nature Reviews Clinical Oncology. 2018;15:47.
Programa de terapia de células T con receptores de antígeno quimérico